Assignee
BIOMARIN PHARM INC
US·107 granted patents·87 pending applications·1,053 citations·filing 2000–2025
Top patents by PatentIndex Score
194 records- 0198US7531341B1Compositions of prokaryotic phenylalanine ammonia-lyase and methods of using compositions thereofBIOMARIN PHARM INC·Filed 2006·Granted May 12, 2009·87 cites·6 claims
- 0297US7981864B2Methods and compositions for targeting proteins across the blood brain barrierBIOMARIN PHARM INC·Filed 2008·Granted Jul 19, 2011·23 cites·8 claims
- 0397US7534595B2Compositions of prokaryotic phenylalanine ammonia-lyase and methods of using compositions thereofBIOMARIN PHARM INC·Filed 2007·Granted May 19, 2009·79 cites·34 claims
- 0497US7442372B2Delivery of therapeutic compounds to the brain and other tissuesBIOMARIN PHARM INC·Filed 2003·Granted Oct 28, 2008·109 cites·49 claims
- 0596US9993481B2Methods and compositions for the treatment of metabolic disordersBIOMARIN PHARM INC·Filed 2016·Granted Jun 12, 2018·11 cites·20 claims
- 0696US9504762B2Adeno-associated virus factor VIII vectorsBIOMARIN PHARM INC·Filed 2014·Granted Nov 29, 2016·28 cites·9 claims
- 0796US8012976B2Dihydropyridophthalazinone inhibitors of poly(ADP-ribose)polymerase (PARP)BIOMARIN PHARM INC·Filed 2009·Granted Sep 6, 2011·40 cites·5 claims
- 0896US7560263B2Compositions of prokaryotic phenylalanine ammonia-lyase and methods of treating cancer using compositions thereofBIOMARIN PHARM INC·Filed 2008·Granted Jul 14, 2009·81 cites·26 claims
- 0996US7537923B2Compositions of prokaryotic phenylalanine ammonia-lyase and methods of treating cancer using compositions thereofBIOMARIN PHARM INC·Filed 2008·Granted May 26, 2009·49 cites·9 claims
- 1095US7566714B2Methods and compositions for the treatment of metabolic disordersBIOMARIN PHARM INC·Filed 2005·Granted Jul 28, 2009·15 cites·46 claims
- 1194US9834587B2Targeted therapeutic lysosomal enzyme fusion proteins and uses thereofBIOMARIN PHARM INC·Filed 2015·Granted Dec 5, 2017·6 cites·12 claims
- 1294US9834588B2Targeted therapeutic lysosomal enzyme fusion proteins and uses thereofBIOMARIN PHARM INC·Filed 2015·Granted Dec 5, 2017·7 cites·12 claims
- 1394US9814762B2Targeted therapeutic proteinsBIOMARIN PHARM INC·Filed 2016·Granted Nov 14, 2017·6 cites·24 claims
- 1494US9340822B2Methods of diagnosing a disease and methods of monitoring treatment of a disease by quantifying a non-reducing end glycan residual compound and comparing to a second biomarkerBIOMARIN PHARM INC·Filed 2014·Granted May 17, 2016·12 cites·23 claims
- 1594US8809009B2Methods of diagnosing a disease and methods of monitoring treatment of a disease by quantifying a non-reducing end glycan residual compound and comparing to a second biomarkerBIOMARIN PHARM INC·Filed 2012·Granted Aug 19, 2014·14 cites·16 claims
- 1694US7790433B2Compositions of prokaryotic phenylalanine ammonia-lyase and methods of treating cancer using compositions thereofBIOMARIN PHARM INC·Filed 2009·Granted Sep 7, 2010·32 cites·6 claims
- 1793US10301369B2Nucleic acids encoding targeted therapeutic lysosomal enzyme fusion proteinsBIOMARIN PHARM INC·Filed 2017·Granted May 28, 2019·5 cites·17 claims
- 1893US9512143B2Histone deacetylase inhibitorsBIOMARIN PHARM INC·Filed 2015·Granted Dec 6, 2016·11 cites·18 claims
- 1992US10646550B2Use of C-type natriuretic peptide variants to treat skeletal dysplasiaBIOMARIN PHARM INC·Filed 2018·Granted May 12, 2020·7 cites·13 claims
- 2092US10300113B2Targeted therapeutic proteinsBIOMARIN PHARM INC·Filed 2017·Granted May 28, 2019·3 cites·17 claims
- 2192US9915649B2Methods of determining the presence, identity, and/or severity of mucopolysaccharidosis (MPS) VI and IVABIOMARIN PHARM INC·Filed 2016·Granted Mar 13, 2018·4 cites·34 claims
- 2292US9771408B2Targeted therapeutic lysosomal enzyme fusion proteins and uses thereofBIOMARIN PHARM INC·Filed 2015·Granted Sep 26, 2017·4 cites·12 claims
- 2392US9222120B2Quantification of non-reducing end glycan residual compounds for determining the presence, identity, or severity of a disease or conditionBIOMARIN PHARM INC·Filed 2014·Granted Dec 29, 2015·13 cites·21 claims
- 2491US11351231B2Lysosomal targeting peptides and uses thereofBIOMARIN PHARM INC·Filed 2017·Granted Jun 7, 2022·3 cites·7 claims
- 2591US10512675B2Adeno-associated virus factor VIII vectors, associated viral particles and therapeutic formulations comprising the sameBIOMARIN PHARM INC·Filed 2016·Granted Dec 24, 2019·9 cites·25 claims
- 2691US9845346B2Targeted therapeutic lysosomal enzyme fusion proteins and uses thereofBIOMARIN PHARM INC·Filed 2015·Granted Dec 19, 2017·4 cites·12 claims
- 2791US9557340B2Assays for detection of phenylalanine ammonia-lyase and antibodies to phenylalanine ammonia-lyaseBIOMARIN PHARM INC·Filed 2015·Granted Jan 31, 2017·7 cites·14 claims
- 2891US9469683B2Lysosomal targeting peptides and uses thereofBIOMARIN PHARM INC·Filed 2014·Granted Oct 18, 2016·12 cites·5 claims
- 2991US9376480B2Targeted therapeutic lysosomal enzyme fusion proteins and uses thereofBIOMARIN PHARM INC·Filed 2013·Granted Jun 28, 2016·6 cites·21 claims
- 3091US7612073B2Methods of administering tetrahydrobiopterin, associated compositions, and methods of measuringBIOMARIN PHARM INC·Filed 2008·Granted Nov 3, 2009·16 cites·11 claims
- 3191US6569661B1Recombinant α-L-iduronidase, methods for producing and purifying the same and methods for treating diseases caused by deficiencies thereofBIOMARIN PHARM INC·Filed 2000·Granted May 27, 2003·63 cites·10 claims
- 3290US11254725B2Targeted therapeutic lysosomal enzyme fusion proteins and uses thereofBIOMARIN PHARM INC·Filed 2019·Granted Feb 22, 2022·2 cites·13 claims
- 3390US9677116B2Quantification of non-reducing end glycan residual compounds for determining the presence, identity, or severity of a disease or conditionBIOMARIN PHARM INC·Filed 2015·Granted Jun 13, 2017·4 cites·30 claims
- 3490US9572870B2Delivery of therapeutic compounds to the brain and other tissuesBIOMARIN PHARM INC·Filed 2015·Granted Feb 21, 2017·6 cites·16 claims
- 3590US8377884B2Variants of C-type natriuretic peptidesBIOMARIN PHARM INC·Filed 2008·Granted Feb 19, 2013·27 cites·24 claims
- 3690US7566462B2Stable tablet formulationBIOMARIN PHARM INC·Filed 2008·Granted Jul 28, 2009·26 cites·20 claims
- 3789US10934534B2Manufacture of active highly phosphorylated human lysosomal sulfatase enzymes and uses thereofBIOMARIN PHARM INC·Filed 2020·Granted Mar 2, 2021·2 cites·29 claims
- 3889US9908899B2Histone deacetylase inhibitorsBIOMARIN PHARM INC·Filed 2016·Granted Mar 6, 2018·5 cites·24 claims
- 3989US8859498B2Targeted therapeutic proteinsBIOMARIN PHARM INC·Filed 2013·Granted Oct 14, 2014·3 cites·20 claims
- 4089US8003126B2Stable tablet formulationBIOMARIN PHARM INC·Filed 2005·Granted Aug 23, 2011·22 cites·22 claims
- 4188USRE48267EVariants of C-type natriuretic peptideBIOMARIN PHARM INC·Filed 2017·Granted Oct 20, 2020·2 cites·76 claims
- 4288US10260084B2Quantification of non-reducing end glycan residual compounds for determining the presence, identity, or severity of a disease or conditionBIOMARIN PHARM INC·Filed 2017·Granted Apr 16, 2019·2 cites·12 claims
- 4388US8999987B2Dihydropyridophthalazinone inhibitors of poly(ADP-ribose)polymerase (PARP)BIOMARIN PHARM INC·Filed 2013·Granted Apr 7, 2015·8 cites·23 claims
- 4488US7947681B2Methods of administering tetrahydrobiopterin, associated compositions, and methods of measuringBIOMARIN PHARM INC·Filed 2009·Granted May 24, 2011·10 cites·28 claims
- 4588US7553653B2Variants and chemically-modified variants of phenylalanine ammonia-lyaseBIOMARIN PHARM INC·Filed 2005·Granted Jun 30, 2009·34 cites·7 claims
- 4687US10563183B2Manufacture of active highly phosphorylated human lysosomal sulfatase enzymes and uses thereofBIOMARIN PHARM INC·Filed 2018·Granted Feb 18, 2020·4 cites·18 claims
- 4787US7722865B2Manufacture of active highly phosphorylated human lysosomal sulfatase enzymes and uses thereofBIOMARIN PHARM INC·Filed 2009·Granted May 25, 2010·15 cites·20 claims
- 4887US7354576B2Methods of treating diseases caused by deficiencies of recombinant α-L-iduronidaseBIOMARIN PHARM INC·Filed 2004·Granted Apr 8, 2008·20 cites·11 claims
- 4986US9796664B2Compositions including 6-aminohexanoic acid derivatives as HDAC inhibitorsBIOMARIN PHARM INC·Filed 2016·Granted Oct 24, 2017·5 cites·19 claims
- 5086US9018201B2Dihydropyridophthalazinone inhibitors of poly(ADP-ribose)polymerase (PARP) for use in treatment of diseases associated with a PTEN deficiencyBIOMARIN PHARM INC·Filed 2013·Granted Apr 28, 2015·8 cites·21 claims
Showing the top 50 of 194 patent records by PatentIndex Score.
Counts cover granted patents and pending applications in the PatentIndex corpus. How scoring works →